Download presentation
Published bySteven Hodges Modified over 9 years ago
1
Fertility Sparing Surgery (FSS) in Gynecologic Oncology
Ali AYHAN, MD. Baskent University School of Medicine Department of Obstetrics & Gynecology Division of Gynecologic Oncology
2
The Main Purpose of Cancer Therapy
High cure Low morbidity High level of quality of life (as a mood, sexuel life, cosmetic appearence, fertility preservation...)
3
All Therapeutic Modalities in Female Cancer
Are associated with infertility (radiation, radical surgery, chemo...)
4
is performed by different centers
Therefore Fertility saving surgery instead of radical in early stage selected gyn/cancer is performed by different centers
5
FSS Objectives Similiar oncologic outcomes to standard therapy Favorable obstetric outcome Benefits > risks Low morbidity and cost
6
Benefits-Risks of FSS Risks Benefits
Increase in probability of recurrence and death Additional surgery Benefits Preservation of fertility Maintanence of endocrine function
7
The Main Requirement of FSS
Preserving of the uterus Preserving at least one ovary
8
Fertility Saving Surgery Depends on
Type and origions of tumor Stage, grade, histology Age, performance Fertility desire Previous infertility problems Close follow up
9
Indications for Fertility Saving Surgery
All germ cell Sex cord stromal (early stage) Borderline ovarian tumor Invasive EOC Cervical Carcinoma Endometrial Carcinoma
10
Adequate surgical staging Removal of affected ovary and tube
Fertility Saving Surgery in Ovarian Tumors (EOC, BOT,MOGCT, Sex Cord Stromal) Adequate surgical staging Removal of affected ovary and tube Preservation of uterus and contralateral ovary Finally evaluation of normal appearing contralateral ovary* and endometrium (D&C)** * For occult metastases * Endometrioid type of epithelial tumors
11
SO TODAY; PROBLEM IS SMALL
FSS in EOC 25-30% of all EOC are early stage at the diagnosis 14% of EOC will occur under 40 years Of these 62% will be stage I and IIa Not all, many of these desire to preserve fertility SO TODAY; PROBLEM IS SMALL
12
Indication for Fertility Sparing Surgery in EOC
1. Stage Ia Grade 1 Stage Ia Grade 2 (limited) 2. Stage Ic, Grade 3, Clear cell + Chemotherapy
13
Main Problems in FSS in EOC
A) In preserved ovary 1) occult metastasis 2) Relapse in spared ovary B) Is there any relationship between relapse, death and preservation of ovary, uterus or other risk factors C) Is there a place of complementary surgery after childbearing
14
Occult Metastasis in Normal Appearing Ovaries
Varies from 7-33% in old literature In new literature, this figures are lower than older (about 2.5%)
15
(ICON1 and ACTION Studies)
Survival 925 patients with early stage disease were subjected to Radical Surgery +Chemo (ICON1 and ACTION Studies) 5 yrs DFS 76% 5 yrs OS 82% J Natl Cancer Inst, 2003:95:
16
FSS Does Not Affect Survival in Early Stage EOC
Survival after FSS in patients with early ovarian cancer Without chemo is about 94%
17
Recurrence, Death and Pregnancy After FSS in EOC
Author Recurrences Ovary / Total Deaths Pregnancy Colombo n=152 11 /18 9 (5.9%) 53 (35%) Brown n=16 2 / 2 2 ? Schilders n=52 3 / 5 26 UK Study n=56 12% Colombo N et al IJGC 2005, Monk BJ, DiSaia PJ, IJGC 2005, Farthing A, BJOG 2006
18
Obstetric Outcome After Fertility Saving Surgery in EOC
Author % Pregnancy Term Delivery Abort. Ectopic Anomaly Colombo 1994 100 (25/25) 16 4 2 Zanetta 1997 56 (20/36) 17 Duska 1999 33.3 (2/6) 1 Morice 2001 22.2 (4/18) 3 Schilder 2002 71 (17/24) 26 5 Total 56.5 (68/109) 64 14
19
Fertility –Sparing Surgery in Borderline Tumors of the Ovary:
15% of all EOC Young age Early stage 95% serous - mucinous Overall survival 95 %
20
Fertility Sparing Surgery in Borderline Ovarian Tumors
Staging Leaving the uterus Some functional ovarian tissue in place Evaluation of endometrial cavity?
21
Ovarian procedures in BOT
BSO (very rare) USO Cystectomy Partial excision Cortical ovarian biopsy for cryopreservation
22
After FSS Recurrence 7.7-31 % Disease related death 0
Donnez, 2003 Morriu, 2001 Cutlieb, 1998 Disease related death 0 Pregnancy rates 31.8, 38.5 and 63.3 % Donnez, 2003
23
Ovarian Tumors of Low Malignant Potential
Study No. Pts. Stage No. Pregn. Lim-Tam 1988 35 IA-III 8 Gotlieb 1998 39 22 in 15 Morris 2000 43 25 in 12 Zanetta 2001 189 44 in 44 Morice 2001 44 17 in 14 Rao 2005 38 6 in 5 Boran 2005 62 10 in 10
24
FSS in MOGCTs 20-25 % of all ovarian neoplasm
Only 3 % of these are malignant Young age Early stage Generally unilateral (Dysgerminoma 12%)
25
Fertility Sparing Surgery In early and selected advanced stage
Full staging Removal of affected ovary Preserving the contraleral ovary Preserving of the uterus + Chemo In early and selected advanced stage
26
The survival in FSS is similar to radical surgery in MOGCTs
Survival in MOGCTs The survival in FSS is similar to radical surgery in MOGCTs
27
Pregnancy after surgery in MOGCTs
Number of patients Pregnancy rate 29/32 76 % 19/20 95 % (Surg +Chemo) 16/20 80 % (Surg +Chemo) 12/12 100 % (Only surgery) Low et al, Zanette et al Gerhenson et al
28
Obstetric Outcome in MOGCT
Author % Pregnancy Term Delivery Abort. Ektopic Anomaly Gershenson 1988 100 (12/16) 22 Perrin 1999 ------ 8 -- Low 2000 95 (19/20) 16 Zanetta 2001 80 (16/20) 26 9 3 Tangir 2003 76 (25/33) 38 2 Toplam 87.75 (72/89) 110 11
29
After Fertility Sparing Surgery:
Oncologic Outcome: After Fertility Sparing Surgery: EOC MOGCTs BOT Survival is similiar to radical surgery
30
FSS in LMS 25% of uterine sarcomas 1% of all uterine malignancies
0.29 of all myomectomies (6815 myoma) 25% premenopausal
31
FSS in LMS Local excision (at least 0.5-1cm tumor free border )
32
Endometrial Cancer Most frequent Gyn.Ca 25% premenopausal
5% under 40 age Type I good prognosis (PCOS) Grade I, EPR + Cure rate %95
33
Pretreatment Evaluation
History (infertility...) Physicial Examination TVUSG D&C Abdominopelvic/ endovajinal coil MRI Ca-125 Laparoscopic evaluation Response to Progesterone or Staging Laparotomy
34
MRI Sensitivity %80 Specifity %100 Before and After Treatment
35
Progestogenic Agents MPA 200-600 /mg/ day Megace 40-160 /mg/day
IUD / Prog Response Rate Hyperplasia with Atypia %83-94 End. Ca % Duration of Treatment Range months Median months Recurrens Hyperplasia with Atypia % 13 End. Ca %
36
Response Rates to Progesterones in Endometrial Cancer
Drug Time Regr. Recur. Pregnancy 7 MA 3 ay 4 2 14 MA/ MPA 1 yıl 9 1 3 12 MA / MPA 3-18 ay MPA 2-14 ay MA / Tam - 8 13 3.5 ay 6 67 16 15 *26 %55 IVF 31 Kım 1997, Randal-Kurman 1997, Kaku 2001, Wang 2002, Gotlieb 2003 *Jadoul-Donnez Fertil Steril 2005;84; 1564
37
FSS in Endometrial Cancer
At young age Well differantiated End. Ca Stage IA, Grade I-II Progestin therapy Evaluation of end with 3 months interval Fertility desire
38
*Tumor <2 cm, Deep Stromal Inv. <1 cm
FSS in Cervical Cancer %27.9 patients < 40 age (SEER) Cx Ca most prevalant in years of age Adenocarcinoma is a problem Squam/ Adeno (except neuroendocrine type) IA-IB1* *Tumor <2 cm, Deep Stromal Inv. <1 cm
39
FSS in Cervical Cancer Cone Only Preinvazive Ia1 LVSI (-) 1a1 LVSI (+)
1b1 2 cm Der:1 cm In selected cases with stage Ib-IIA ovarian transposition,oocyte and/or embryo criopreservation Cone Only Pelvic LND* + Radikal Trachelectomy** *Endoscopic/ Laparotomy / Sentinel Node **Vaginal /Abdominal
40
In IA1 LVSI (-) CONE RE-CONE
Tumor free margin and post-cone negative ECC Positive margin or positive ECC RE-CONE
41
Clinical importance of margin and ECC
Variables Residual tumor Margin Negative 3% Positive 22% Margin and ECC 4% 33%
42
Pelvic Node Metastasis in Stage IA1
Depth of Invasion LNM + 1mm or less 0,1 1-3 mm 0,5
43
Stage IA1 with LVSI (+) IA2
Pelvic lymphadenectomy Radical trachelectomy* plus Cervical cerclage *Free margin >at least 5mm-1 cm
44
Why lymphadenectomy in Stage IA2
Variables % LNM Metas. LNM + 7.3 Invasive Rec 3.1 Death of Dis. 2.3 Van Nagell et al..... Creasman et al
45
Pelvic lymphadenectomy + Radical trachelectomy
FSS in Stage IB1 Lesion ≤ 2cm Depth of Inv ≤ 1cm LNM negative Upper cervical involvement (-) Pelvic lymphadenectomy + Radical trachelectomy
46
Radical trachelectomy (1994 Dargent)
Removal of primary tumor Parametrectomy 1/3 upper vaginectomy Preserving uterine fundus Pelvic lymphadenectomy
47
Radical trachelectomy
Abdominal Vaginal Lymphadenectomy (Open and Endoscopic)
48
Radical trachelectomy and
No difference between Radical trachelectomy and Radical hysterectomy for Recurrence and Death
55
Pregnancy Results after VRT
Fertility Desire No.of Pregn/ Patient Livebirth 96 42 56/33 34 72 48/31 28 93 39 22/18 18 30 13 14/8 9 19 4 4/3 2 10 4/4 315 144 148/97 Mathevet 2003, Plante 2004, Steed-Covens 2003, Shephard 2001, Burnett 2003, Schlaerth 2003 Fertil Steril 2005;84:156
56
Reproductive Outcome after Trachelectomy
%25-43 infertility Pre-operative (STD) ve post-operative (stenosis) Loss of fertility desire in %25 Pregnancy rate %71 Delivery rate % 41 First trimester loss %21 Second trimester loss %8 Preterm delivery %20-%30 Cervical Insufficiency (Cerclage Saling Procedure, Ab, USG ??) PPROM Informed Consent !!!!! Boss et al, Gynecol Oncol, 2005
57
Conclusion-I Fertility Preservation Options in Females
Conservative surgery Embryo cryopreservation Oocyte cryopreservation Ovarian tissue cryopreservation Ovarian supression (GnRH analogs)
58
Conclusion-II Fertility Preservation Strategies
Treatment can be delayed Treatment cannot be delayed IVF-Embriyo Freezing Oocyte freezing Ovarian Tissue Freezing In vitro maturation in high risk for ovarian involvement Add TMX or Aromatase Inhibitors for Est-sensitive
59
Thank you…
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.